InsiderTrades.com logo

FTH Insider Trading

Insider Ownership Percentage: 7.00%
Insider Buying (Last 12 Months): $2,530,490.88
Insider Selling (Last 12 Months): $1,492,218.80

Sensei Biotherapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Sensei Biotherapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Sensei Biotherapeutics Share Price & Price History

Current Price: $24.48
Price Change: ▼ Price Decrease of -0.11 (-0.45%)
As of 08/6/2026 04:00 PM ET

This chart shows the closing price history over time for FTH up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Sensei Biotherapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/1/2026Brian C StephensonCFOBuy5,000$23.50$117,500.0046,688View SEC Filing Icon  
6/30/2026Brian C StephensonCFOBuy7,803$24.25$189,222.7541,688View SEC Filing Icon  
6/29/2026Brian C StephensonCFOBuy831$23.34$19,395.5433,885View SEC Filing Icon  
6/26/2026Brian C StephensonCFOBuy6,250$24.95$155,937.5033,054View SEC Filing Icon  
6/24/2026Brian C StephensonCFOBuy9,391$26.13$245,386.8326,804View SEC Filing Icon  
6/23/2026Brian C StephensonCFOBuy9,230$24.36$224,842.8017,413View SEC Filing Icon  
6/22/2026Anand Kiran ParikhCEOBuy2,806$19.76$55,446.56764,234View SEC Filing Icon  
6/22/2026Brian C StephensonCFOBuy8,183$22.13$181,089.798,183View SEC Filing Icon  
6/1/2026James PeyerMajor ShareholderSell25,000$20.02$500,500.00130,142View SEC Filing Icon  
4/7/2026Millennium Management LlcMajor ShareholderBuy1,108$33.38$36,985.04133,986View SEC Filing Icon  
4/7/2026Millennium Management LlcMajor ShareholderSell8,151$31.01$252,762.51133,986View SEC Filing Icon  
4/6/2026Millennium Management LlcMajor ShareholderSell1,259$31.06$39,104.54141,029View SEC Filing Icon  
4/6/2026Millennium Management LlcMajor ShareholderBuy1,104$31.02$34,246.08141,029View SEC Filing Icon  
4/2/2026Millennium Management LlcMajor ShareholderSell7,666$32.12$246,231.92144,974View SEC Filing Icon  
4/2/2026Millennium Management LlcMajor ShareholderBuy2,003$35.01$70,125.03144,974View SEC Filing Icon  
4/1/2026Millennium Management LlcMajor ShareholderSell1,150$31.65$36,397.50147,731View SEC Filing Icon  
4/1/2026Millennium Management LlcMajor ShareholderBuy6,175$34.49$212,975.75147,731View SEC Filing Icon  
3/31/2026Millennium Management LlcMajor ShareholderSell1,591$25.49$40,554.59146,657View SEC Filing Icon  
3/31/2026Millennium Management LlcMajor ShareholderBuy6,005$28.16$169,100.80146,657View SEC Filing Icon  
3/30/2026Millennium Management LlcMajor ShareholderSell888$26.61$23,629.68145,678View SEC Filing Icon  
3/30/2026Millennium Management LlcMajor ShareholderBuy9,533$25.86$246,523.38145,678View SEC Filing Icon  
3/27/2026Millennium Management LlcMajor ShareholderBuy15,321$26.61$407,691.81142,360View SEC Filing Icon  
3/27/2026Millennium Management LlcMajor ShareholderSell505$26.81$13,539.05142,360View SEC Filing Icon  
3/26/2026Millennium Management LlcMajor ShareholderSell1,857$28.12$52,218.84131,370View SEC Filing Icon  
3/26/2026Millennium Management LlcMajor ShareholderBuy5,731$28.62$164,021.22131,370View SEC Filing Icon  
12/9/2025James PeyerMajor ShareholderSell3,507$7.96$27,915.72155,142View SEC Filing Icon  
12/8/2025James PeyerMajor ShareholderSell3,105$8.59$26,671.95158,254View SEC Filing Icon  
12/5/2025James PeyerMajor ShareholderSell16,295$11.50$187,392.50161,359View SEC Filing Icon  
12/4/2025James PeyerMajor ShareholderSell5,000$9.06$45,300.00177,654View SEC Filing Icon  
9/11/2023John CelebiCEOBuy25$17.00$425.005,565View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Sensei Biotherapeutics (NASDAQ:FTH)

10.50% of Sensei Biotherapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at FTH by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Sensei Biotherapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/20/2026Vivo Capital LLC722,020$22.76M1.9%N/A53.882%Search for SEC Filing on Google Icon
5/19/2026Bank of America Corp DE33,025$1.04M0.0%+10,692.5%2.465%Search for SEC Filing on Google Icon
5/19/2026Stempoint Capital LP132,873$4.19M0.8%N/A9.916%Search for SEC Filing on Google Icon
5/14/2026Renaissance Technologies LLC32,041$1.01M0.0%+178.2%2.391%Search for SEC Filing on Google Icon
2/18/2026Ikarian Capital LLC21,351$0.23M0.0%-5.1%1.695%Search for SEC Filing on Google Icon
2/12/2026Renaissance Technologies LLC11,516$0.12M0.0%+10.6%0.913%Search for SEC Filing on Google Icon
2/13/2025XTX Topco Ltd62,903$31K0.0%+351.7%0.250%Search for SEC Filing on Google Icon
2/13/2025Renaissance Technologies LLC156,800$77K0.0%-27.3%0.623%Search for SEC Filing on Google Icon
11/15/2024National Bank of Canada FI45,575$27K0.0%+355.8%0.181%Search for SEC Filing on Google Icon
11/14/2023Newtyn Management LLC1,800,000$1.35M0.3%-1.5%7.200%Search for SEC Filing on Google Icon
11/14/2022RA Capital Management L.P.683,529$1.06M0.0%-5.5%2.225%Search for SEC Filing on Google Icon
7/22/2022Truist Financial Corp19,934$45K0.0%-60.5%0.065%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Sensei Biotherapeutics logo
Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Read More on Sensei Biotherapeutics

Today's Range

Now: $24.48
Low: $23.90
High: $25.70

50 Day Range

MA: N/A

52 Week Range

Now: $24.48
Low: $7.20
High: $37.90

Volume

205,730 shs

Average Volume

328,529 shs

Market Capitalization

$32.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Sensei Biotherapeutics?

Sensei Biotherapeutics' top insider shareholders include:
  1. Anand Kiran Parikh (CEO)
  2. James Peyer (Major Shareholder)
  3. Millennium Management Llc (Major Shareholder)
  4. Apeiron Investment Group Ltd (Major Shareholder)
  5. Brian C Stephenson (CFO)
  6. John Celebi (CEO)
  7. Cambrian Biopharma Inc (Major Shareholder)
  8. James Peyer (Director)
  9. Robert Hamilton Pierce (Insider)
  10. Thomas G Ricks (Director)
Learn More about top insider investors at Sensei Biotherapeutics.

Sensei Biotherapeutics Active Insiders

Thomas G Ricks
Director
James Peyer
James Peyer
Director
1 recent trades
Robert Hamilton Pierce
Robert Hamilton Pierce (Age 61)
Insider